Form 4: Teva Pharmaceutical Industries: Executive Vice President Mark Sabag Reports Share Transactions

Executive Vice President of International Markets at Teva Pharmaceutical Industries, Mark Sabag, reports the vesting and subsequent disposal of 24,900 restricted share units, resulting in the acquisition of 24,900 ordinary shares and a decrease in his holdings of restricted share units.

Summary

• Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries, reported transactions involving restricted share units and ordinary shares.
• On March 3, 2025, 24,900 restricted share units vested, each representing a contingent right to receive one ordinary share or its cash value.
• Upon vesting, these restricted share units were converted into 24,900 ordinary shares.
• Following the reported transaction, Sabag directly owns 229,864 ordinary shares and 49,801 restricted share units.
• The restricted share units were granted on March 3, 2023, and vest annually.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Future Outlook

The document indicates future vesting dates for the remaining restricted share units held by Mark Sabag, suggesting continued equity-based compensation.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and is common among publicly traded companies. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Executive compensation packages often include restricted share units as a way to align management's interests with those of shareholders.
• The vesting schedule of these units is typical, with annual vesting over a period of several years.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The vesting of restricted share units can have a minor dilutive effect on existing shareholders.
• The transaction provides insight into executive compensation practices, which is of interest to shareholders.

Key Dates